PTC Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell PTCT and other ETFs, options, and stocks.

About PTCT

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ. 

CEO
Matthew B. Klein
CEOMatthew B. Klein
Employees
991
Employees991
Headquarters
Warren, New Jersey
HeadquartersWarren, New Jersey
Founded
1998
Founded1998
Employees
991
Employees991

PTCT Key Statistics

Market cap
4.98B
Market cap4.98B
Price-Earnings ratio
-100.49
Price-Earnings ratio-100.49
Dividend yield
—
Dividend yield—
Average volume
1.12M
Average volume1.12M
High today
—
High today—
Low today
—
Low today—
Open price
$59.30
Open price$59.30
Volume
0.00
Volume0.00
52 Week high
$90.87
52 Week high$90.87
52 Week low
$58.80
52 Week low$58.80

Stock Snapshot

With a market cap of 4.98B, PTC Therapeutics(PTCT) trades at $59.67. The stock has a price-to-earnings ratio of -100.49.

During the trading day, PTC Therapeutics(PTCT) stock saw an opening price of $59.30, a peak of —, and a bottom of —.

Trading volume for PTC Therapeutics(PTCT) stock has reached 0, versus its average volume of 1.12M.

The stock's 52-week range extends from a low of $58.80 to a high of $90.87.

The stock's 52-week range extends from a low of $58.80 to a high of $90.87.

PTCT News

TipRanks 10h
PTC Therapeutics assumed with a Buy at UBS

UBS analyst Joon Lee assumed coverage of PTC Therapeutics (PTCT) with a Buy rating with a price target of $90, up from $80. The firm states that its Buy thesis...

Investing.com 1d
PTC Therapeutics CLO Mark Boulding sells $12,337 in stock - Investing.com

...

PTC Therapeutics CLO Mark Boulding sells $12,337 in stock - Investing.com
TipRanks 7d
PTC Therapeutics price target lowered to $75 from $85 at RBC Capital

RBC Capital lowered the firm’s price target on PTC Therapeutics (PTCT) to $75 from $85 and keeps a Sector Perform rating on the shares as part of a broader rese...

Analyst ratings

81%

of 16 ratings
Buy
81.3%
Hold
12.5%
Sell
6.3%

People also own

Based on the portfolios of people who own PTCT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.